Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|April 27, 2019
Interchangeability Of Biological Drug Products-FDA Draft GuidanceLaszlo Endrenyi, Richard Markus
BJU International|December 12, 2007
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastasesFred Saad, Richard Markus, Carsten Goessl
Cancer Chemotherapy and Pharmacology|March 26, 2017
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjectsVladimir Hanes, Vincent Chow, Nan Zhang, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2018
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjectsVladimir Hanes, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2017
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2017
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
The Journal of Urology|December 14, 2012
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trialKarim Fizazi, Linda Bosserman, Guozhi Gao, et al.
The Journal of Urology|June 16, 2009
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trialKarim Fizazi, Linda Bosserman, Guozhi Gao, et al.
Annals of the Rheumatic Diseases|July 29, 2016
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumabPrimal Kaur, Vincent Chow, Nan Zhang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 26, 2017
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare CommunityRichard Markus, Jennifer Liu, Monica Ramchandani, et al.
Pageof 2